AI and PET-MRI scans aim to personalize cancer radiation therapy

NCT ID NCT06256705

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is looking at people with a rare type of digestive system cancer called GEP-NET who are receiving a targeted radiation therapy (PRRT). Researchers will use special PET-MRI scans and artificial intelligence to find patterns that predict how well the treatment works. The goal is to better select patients who will benefit most from PRRT. About 80 participants will be followed for 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
68Ga-DOTATOC PET-MRI imaging
What this could lead to
If successful, this could lead to better ways to predict which patients will benefit most from targeted radiation therapy for GEP-NET tumors.
What could go wrong
This is an observational imaging study, not a treatment trial. It will not directly test a new therapy, and results may not change current practice for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hépato-gastro-entérologie, cancérologie digestive et assistance nutritionnelle - CHU Nantes

    ACTIVE_NOT_RECRUITING

    Nantes, 44000, France

  • Médecine nucléaire - CHU Nantes

    RECRUITING

    Nantes, 44000, France

  • Médecine nucléaire et Biophysique - Beaujon

    RECRUITING

    Clichy, 92110, France

  • Pancréatologie et Oncologie Digestive - Beaujon

    RECRUITING

    Clichy, 92110, France

  • Service de Médecine Nucléaire, Groupe Hospitalier Bichat-Claude Bernard

    ACTIVE_NOT_RECRUITING

    Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.